Clinical trial
Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients…
NCT00387699 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00387699 |
|---|---|
| Title | Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
| Official title | Phase II Trial of Bevacizumab in Combination With Cisplatin/Etoposide and Twice Daily Radiation for Patients With Limited-Stage Small Cell Lung Cancer |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | bevacizumab, cisplatin, etoposide, radiation therapy |
| Enrollment | 79 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Apr 1, 2014 |
| First posted | Oct 13, 2006 |
| Last update posted | Apr 28, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: